Episode
Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.
- Podcast
- Business Of Biotech
- Published
- Jun 1, 2026
- Duration seconds
- 2992
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/derisking-cns-drug-development-with-tortugas-neuroscience-s-jeff-jonas-m-d.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen. Jeff explains his strategy of chasing fast proof of safety and efficacy in humans, not animals, and talks about what product differentiation looks like in brain disorders, from adjusting indication targets to conducting head-to-head trials. He al...